Ireland· IE-PA-EU/1/20/1481/003
Vocabria 600 mg prolonged-release suspension for injection
A cabotegravir product containing cabotegravir, registered in Ireland by ViiV Healthcare BV. The same ATC class is registered in 14 of our 19 countries.
Checked against HPRA (Ireland) on
Informational only — not a medical device.
Where it is registered
Cabotegravir is registered in 14 of 19 countries.
Countries holding a registration under ATC J05AJ04 (cabotegravir), each read from that country’s own register.
- This record: Ireland, from HPRA (Ireland)
- 9 of them publish a price we can compare per daily dose
Cabotegravir · ATC J05AJ04
14 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Icelandprice
- Ireland
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of cabotegravir costs, country by country.
Normalised to the WHO defined daily dose (30 mg), so markets compare like for like.
- 2 markets with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Cabotegravir · price per daily dose (30 mg)
USD · FX 28 Sept 2026
- CH Switzerland$24.58
- FR France$20.75
The record
At a glance
HPRA (Ireland)- Active substance
- cabotegravir
- Manufacturer
- ViiV Healthcare BV
- Country
- Ireland (IE)
- ATC code
- J05AJ04
- ATC class
- Cabotegravir
- Defined daily dose
- 30 mg, O
- Reimbursed
- Not published by this register
- Source register
- HPRA (Ireland)
- Last checked
- September 28, 2026
Packs & prices · 1
- ie_pa_numberEU/1/20/1481/003
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
13 interactions on record for cabotegravir.
Graded by severity as the source publishes them — 13 moderate. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Cabotegravir · interactions on record
13 records
- 13 moderate
Most severe, free to view
- Magnesium carbonateA02AA01moderate
- Magnesium oxideA02AA02moderate
- Magnesium hydroxideA02AA04moderate
- Kombinationen von AluminiumsalzenA02AB10moderate
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Cabotegravir in 14 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- FinlandApretudeViiV Healthcare BV
- FranceAPRETUDE 600 mg, suspension injectable à libération prolongéeVIIV HEALTHCARE (PAYS-BAS)
- CzechiaAPRETUDEViiV Healthcare BV, Amersfoort
- IcelandApretudeViiV Healthcare BV
- BelgiumApretude 30 mgViiV Healthcare
- SwedenApretude 30 mg Filmdragerad tablettViiV Healthcare BV
- NetherlandsApretude 30 mg filmomhulde tabletViiV Healthcare B.V.
- PolandApretudeViiV Healthcare BV
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Apretude, Vocabria
- Liechtenstein · Apretude, Vocabria
- Norway · Apretude, Vocabria
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of HPRA (Ireland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/ab90d726-f614-45ee-b220-7c0f4fcd2e71 GET /v1/drugs/ab90d726-f614-45ee-b220-7c0f4fcd2e71?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Prolonged-release suspension for injection",
"routes": [
"Intramuscular use"
],
"source": "hpra",
"atc_all": [
"J05AJ04",
"J05AX"
],
"strength": null,
"pa_number": "EU/1/20/1481/003",
"substances": [
"cabotegravir"
],
"legal_basis": "Full application (Article 8(3) of Directive No 2001/83/EC)",
"market_info": "Unknown",
"authorised_at": "17/12/2020",
"dispensing_status": "Product subject to prescription which may not be renewed (A)",
"registration_status": "AU",
"supply_legal_status": "Supply through pharmacies only",
"interchangeable_code": null
}See everything about cabotegravir.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.